Defining the Riddle in Order to Solve It: There Is More Than One “Parkinson's Disease”

BACKGROUND More than 200 years after James Parkinsondescribed a clinical syndrome based on his astute observations, Parkinson's disease (PD) has evolved into a complex entity, akin to the heterogeneity of other complex human syndromes of the central nervous system such as dementia, motor neuron disease, multiple sclerosis, and epilepsy. Clinicians, pathologists, and basic science researchers evolved arrange of concepts andcriteria for the clinical, genetic, mechanistic, and neuropathological characterization of what, in their best judgment, constitutes PD. However, these specialists have generated and used criteria that are not necessarily aligned between their different operational definitions, which may hinder progress in solving the riddle of the distinct forms of PD and ultimately how to treat them. OBJECTIVE This task force has identified current in consistencies between the definitions of PD and its diverse variants in different domains: clinical criteria, neuropathological classification, genetic subtyping, biomarker signatures, and mechanisms of disease. This initial effort for "defining the riddle" will lay the foundation for future attempts to better define the range of PD and its variants, as has been done and implemented for other heterogeneous neurological syndromes, such as stroke and peripheral neuropathy. We strongly advocate for a more systematic and evidence-based integration of our diverse disciplines by looking at well-defined variants of the syndrome of PD. CONCLUSION Accuracy in defining endophenotypes of "typical PD" across these different but interrelated disciplines will enable better definition of variants and their stratification in therapeutic trials, a prerequisite for breakthroughs in the era of precision medicine. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

[1]  D. Arkadir,et al.  Embracing Monogenic Parkinson's Disease: The MJFF Global Genetic PD Cohort , 2023, Movement disorders : official journal of the Movement Disorder Society.

[2]  D. Hernandez,et al.  Polygenic Parkinson's Disease Genetic Risk Score as Risk Modifier of Parkinsonism in Gaucher Disease , 2022, medRxiv.

[3]  Yen F. Tai,et al.  Longitudinal clinical and biomarker characteristics of non-manifesting LRRK2 G2019S carriers in the PPMI cohort , 2022, npj Parkinson's Disease.

[4]  T. Hatano,et al.  Age Cutoff for Early‐Onset Parkinson's Disease: Recommendations from the International Parkinson and Movement Disorder Society Task Force on Early Onset Parkinson's Disease , 2022, Movement disorders clinical practice.

[5]  H. Soreq,et al.  Cerebrospinal fluid and blood profiles of transfer RNA fragments show age, sex and Parkinson’s disease-related changes , 2022, bioRxiv.

[6]  T. Feng,et al.  Oral Mucosa Derived α−Synuclein as a Potential Diagnostic Biomarker for Parkinson′s Disease , 2022, Frontiers in Aging Neuroscience.

[7]  G. Disanto,et al.  Alpha-synuclein oligomers and small nerve fiber pathology in skin are potential biomarkers of Parkinson’s disease , 2021, NPJ Parkinson's disease.

[8]  James E. Tomkins,et al.  Genomewide Association Studies of LRRK2 Modifiers of Parkinson's Disease , 2021, Annals of neurology.

[9]  Alan J. Thomas,et al.  Concomitant neurodegenerative pathologies contribute to the transition from mild cognitive impairment to dementia , 2021, Alzheimer's & dementia : the journal of the Alzheimer's Association.

[10]  A. Kakita,et al.  Genetic Variations and Neuropathologic Features of Patients with PRKN Mutations , 2021, Movement disorders : official journal of the Movement Disorder Society.

[11]  K. Jellinger,et al.  Neuropathological consensus criteria for the evaluation of Lewy pathology in post-mortem brains: a multi-centre study , 2021, Acta Neuropathologica.

[12]  A. Singleton,et al.  Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson’s Disease Progression , 2020, Movement disorders : official journal of the Movement Disorder Society.

[13]  M. Farrer,et al.  Neuropathological findings in PINK1-associated Parkinson's disease. , 2020, Parkinsonism & related disorders.

[14]  A. Singleton,et al.  Genetic and Phenotypic Basis of Autosomal Dominant Parkinson's Disease in a Large Multi-Center Cohort , 2020, Frontiers in Neurology.

[15]  A. Singleton,et al.  Characterization of Recessive Parkinson Disease in a Large Multicenter Study , 2020, Annals of neurology.

[16]  C. B. Sanz-Morère,et al.  Iron Imaging as a Diagnostic Tool for Parkinson's Disease: A Systematic Review and Meta-Analysis , 2020, Frontiers in Neurology.

[17]  E. Valente,et al.  PINK1 and Parkin: The odd couple , 2020, Neuroscience Research.

[18]  A. Kriško,et al.  SARS‐CoV‐2: At the Crossroad Between Aging and Neurodegeneration , 2020, Movement disorders : official journal of the Movement Disorder Society.

[19]  K. Nilsson,et al.  Discriminating α-synuclein strains in Parkinson’s disease and multiple system atrophy , 2020, Nature.

[20]  E. Gerhardt,et al.  Synucleinopathies: Where we are and where we need to go , 2020, Journal of neurochemistry.

[21]  Alan J. Thomas,et al.  Amyloid Imaging and Longitudinal Clinical Progression in Dementia With Lewy Bodies. , 2019, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[22]  P. Lockhart,et al.  Distribution of Parkinson’s disease associated RAB39B in mouse brain tissue , 2019, Molecular Brain.

[23]  J. Trojanowski,et al.  Alzheimer’s disease tau is a prominent pathology in LRRK2 Parkinson’s disease , 2019, Acta Neuropathologica Communications.

[24]  K. Marder,et al.  Movement disorders rounds: A case of missing pathology in a patient with LRRK2 Parkinson's disease. , 2019, Parkinsonism & related disorders.

[25]  Sebastian Heinzel,et al.  Update of the MDS research criteria for prodromal Parkinson's disease , 2019, Movement disorders : official journal of the Movement Disorder Society.

[26]  T. Outeiro,et al.  In vitro models of synucleinopathies: informing on molecular mechanisms and protective strategies , 2019, Journal of neurochemistry.

[27]  J. Attems,et al.  Clinical and neuropathological differences between Parkinson's disease, Parkinson's disease dementia and dementia with Lewy bodies – current issues and future directions , 2019, Journal of neurochemistry.

[28]  B. Thelma,et al.  Expanding the canvas of PRKN mutations in familial and early-onset Parkinson disease. , 2019, Parkinsonism & related disorders.

[29]  E. Sidransky,et al.  Glucocerebrosidase and its relevance to Parkinson disease , 2019, Molecular Neurodegeneration.

[30]  K. Jellinger Neuropathology and pathogenesis of extrapyramidal movement disorders: a critical update. II. Hyperkinetic disorders , 2019, Journal of Neural Transmission.

[31]  C. Jack,et al.  Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report , 2019, Brain : a journal of neurology.

[32]  P. Calabresi,et al.  Neurofilament light chain as a biomarker in neurological disorders , 2019, Journal of Neurology, Neurosurgery, and Psychiatry.

[33]  A. Strafella,et al.  Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System , 2019, Alzheimer's & Dementia.

[34]  Claudio Soto,et al.  Comparative study of cerebrospinal fluid α‐synuclein seeding aggregation assays for diagnosis of Parkinson's disease , 2019, Movement disorders : official journal of the Movement Disorder Society.

[35]  T. Simuni,et al.  New Era in disease modification in Parkinson's disease: Review of genetically targeted therapeutics. , 2019, Parkinsonism & related disorders.

[36]  Yinzhou Wang,et al.  Increased DJ-1 and α-Synuclein in Plasma Neural-Derived Exosomes as Potential Markers for Parkinson’s Disease , 2019, Front. Aging Neurosci..

[37]  C. Tanner,et al.  Reproducibility of data-driven Parkinson's disease subtypes for clinical research. , 2018, Parkinsonism & related disorders.

[38]  N. Hattori,et al.  Isolated nigral degeneration without pathological protein aggregation in autopsied brains with LRRK2 p.R1441H homozygous and heterozygous mutations , 2018, Acta neuropathologica communications.

[39]  I. König,et al.  Genotype‐phenotype relations for the Parkinson's disease genes SNCA, LRRK2, VPS35: MDSGene systematic review , 2018, Movement disorders : official journal of the Movement Disorder Society.

[40]  A. Brice,et al.  The genetic landscape of Parkinson's disease. , 2018, Revue neurologique.

[41]  C. Adler,et al.  Immunohistochemical Method and Histopathology Judging for the Systemic Synuclein Sampling Study (S4) , 2018, Journal of neuropathology and experimental neurology.

[42]  T. Postmus Genetics of Parkinson's disease , 2018 .

[43]  E. Tolosa,et al.  Lack of central and peripheral nervous system synuclein pathology in R1441G LRRK2-associated Parkinson’s disease , 2018, Journal of Neurology, Neurosurgery, and Psychiatry.

[44]  Z. Gan-Or,et al.  GBA-Associated Parkinson’s Disease and Other Synucleinopathies , 2018, Current Neurology and Neuroscience Reports.

[45]  I. König,et al.  Genotype‐Phenotype Relations for the Parkinson's Disease Genes Parkin, PINK1, DJ1: MDSGene Systematic Review , 2018, Movement disorders : official journal of the Movement Disorder Society.

[46]  K. Marder,et al.  Application of the Movement Disorder Society prodromal criteria in healthy G2019S‐LRRK2 carriers , 2018, Movement disorders : official journal of the Movement Disorder Society.

[47]  Norbert Schuff,et al.  Longitudinal Change of Clinical and Biological Measures in Early Parkinson's Disease: Parkinson's Progression Markers Initiative Cohort , 2018, Movement disorders : official journal of the Movement Disorder Society.

[48]  M. Stamelou,et al.  Selective cognitive impairment and hyposmia in p.A53T SNCA PD vs typical PD , 2018, Neurology.

[49]  B. Ritz,et al.  Association of Polygenic Risk Score With Cognitive Decline and Motor Progression in Parkinson Disease , 2018, JAMA neurology.

[50]  K. Marder,et al.  Progression in the LRRK2-Asssociated Parkinson Disease Population , 2018, JAMA neurology.

[51]  A. Schapira,et al.  Glucocerebrosidase and Parkinson Disease: Molecular, Clinical, and Therapeutic Implications , 2018, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.

[52]  C. Franceschi,et al.  Aging and Parkinson's Disease: Inflammaging, neuroinflammation and biological remodeling as key factors in pathogenesis , 2018, Free radical biology & medicine.

[53]  J. Del-Aguila,et al.  Parkinson disease polygenic risk score is associated with Parkinson disease status and age at onset but not with alpha-synuclein cerebrospinal fluid levels , 2017, BMC Neurology.

[54]  S. Schneider,et al.  Neuropathology of genetic synucleinopathies with parkinsonism: Review of the literature , 2017, Movement disorders : official journal of the Movement Disorder Society.

[55]  J. Ferreira,et al.  Posttranslational modifications of blood-derived alpha-synuclein as biochemical markers for Parkinson’s disease , 2017, Scientific Reports.

[56]  R. Nunes,et al.  Neuromelanin magnetic resonance imaging of the substantia nigra in LRRK2‐related Parkinson's disease , 2017, Movement disorders : official journal of the Movement Disorder Society.

[57]  K. Marek,et al.  Candidate inflammatory biomarkers display unique relationships with alpha-synuclein and correlate with measures of disease severity in subjects with Parkinson’s disease , 2017, Journal of Neuroinflammation.

[58]  A. Puschmann New Genes Causing Hereditary Parkinson’s Disease or Parkinsonism , 2017, Current Neurology and Neuroscience Reports.

[59]  R. Postuma,et al.  Application of the movement disorder society prodromal Parkinson's disease research criteria in 2 independent prospective cohorts , 2017, Movement disorders : official journal of the Movement Disorder Society.

[60]  Nicholas W Wood,et al.  Genome-wide Pleiotropy Between Parkinson Disease and Autoimmune Diseases , 2017, JAMA neurology.

[61]  A. Dagher,et al.  Clinical criteria for subtyping Parkinson’s disease: biomarkers and longitudinal progression , 2017, Brain : a journal of neurology.

[62]  R. Barker,et al.  Utility of the new Movement Disorder Society clinical diagnostic criteria for Parkinson's disease applied retrospectively in a large cohort study of recent onset cases , 2017, Parkinsonism & related disorders.

[63]  J. Attems The multi-morbid old brain , 2017, Acta Neuropathologica.

[64]  J. Attems,et al.  Interactions of pathological proteins in neurodegenerative diseases , 2017, Acta Neuropathologica.

[65]  Oury Monchi,et al.  The role of high‐field magnetic resonance imaging in parkinsonian disorders: Pushing the boundaries forward , 2017, Movement disorders : official journal of the Movement Disorder Society.

[66]  N. Bouslam,et al.  LRRK2 G2019S Mutation: Prevalence and Clinical Features in Moroccans with Parkinson's Disease , 2017, Parkinson's disease.

[67]  B. Mollenhauer,et al.  Development of a Biochemical Diagnosis of Parkinson Disease by Detection of &agr;-Synuclein Misfolded Aggregates in Cerebrospinal Fluid , 2017, JAMA neurology.

[68]  M. Stamelou,et al.  Frontotemporal dementia as the presenting phenotype of p.A53T mutation carriers in the alpha-synuclein gene. , 2017, Parkinsonism & related disorders.

[69]  M. Esiri,et al.  Alpha‐synuclein RT‐QuIC in the CSF of patients with alpha‐synucleinopathies , 2016, Annals of clinical and translational neurology.

[70]  M. Stamelou,et al.  Motor and Nonmotor Features of Carriers of the p.A53T Alpha‐Synuclein Mutation: A Longitudinal Study , 2016, Movement disorders : official journal of the Movement Disorder Society.

[71]  G. Halliday,et al.  Increased peripheral inflammation in asymptomatic leucine‐rich repeat kinase 2 mutation carriers , 2016, Movement disorders : official journal of the Movement Disorder Society.

[72]  I. Alonso,et al.  DJ-1 linked parkinsonism (PARK7) is associated with Lewy body pathology. , 2016, Brain : a journal of neurology.

[73]  Simon C. Potter,et al.  Loss of VPS13C Function in Autosomal-Recessive Parkinsonism Causes Mitochondrial Dysfunction and Increases PINK1/Parkin-Dependent Mitophagy. , 2016, American journal of human genetics.

[74]  Günther Deuschl,et al.  MDS research criteria for prodromal Parkinson's disease , 2015, Movement disorders : official journal of the Movement Disorder Society.

[75]  G. Deuschl,et al.  MDS clinical diagnostic criteria for Parkinson's disease , 2015, Movement disorders : official journal of the Movement Disorder Society.

[76]  Jean-François Gagnon,et al.  New Clinical Subtypes of Parkinson Disease and Their Longitudinal Progression: A Prospective Cohort Comparison With Other Phenotypes. , 2015, JAMA neurology.

[77]  A. Desautels,et al.  GBA mutations are associated with Rapid Eye Movement Sleep Behavior Disorder , 2015, Annals of clinical and translational neurology.

[78]  S. Lehéricy,et al.  High nigral iron deposition in LRRK2 and Parkin mutation carriers using R2* relaxometry , 2015, Movement disorders : official journal of the Movement Disorder Society.

[79]  Carlos Ortiz-de-Solorzano,et al.  Automated Neuromelanin Imaging as a Diagnostic Biomarker for Parkinson's Disease , 2015, Movement disorders : official journal of the Movement Disorder Society.

[80]  A. Schapira Glucocerebrosidase and Parkinson disease: Recent advances , 2015, Molecular and Cellular Neuroscience.

[81]  T. Simuni,et al.  Is There a Role for DAT-SPECT Imaging in a Specialty Movement Disorders Practice? , 2015, Neurodegenerative Diseases.

[82]  Zuzana Walker,et al.  Is ioflupane I123 injection diagnostically effective in patients with movement disorders and dementia? Pooled analysis of four clinical trials , 2014, BMJ Open.

[83]  W. Chung,et al.  Comparison of Parkinson risk in Ashkenazi Jewish patients with Gaucher disease and GBA heterozygotes. , 2014, JAMA neurology.

[84]  Ludovico Minati,et al.  Substantia nigra in Parkinson’s disease: a multimodal MRI comparison between early and advanced stages of the disease , 2014, Neurological Sciences.

[85]  J. Ioannidis,et al.  A multi-centre clinico-genetic analysis of the VPS35 gene in Parkinson disease indicates reduced penetrance for disease-associated variants , 2012, Journal of Medical Genetics.

[86]  A. Kupsch,et al.  Changes in Clinical Management and Diagnosis following DaTscan™ SPECT Imaging in Patients with Clinically Uncertain Parkinsonian Syndromes: A 12-Week Follow-Up Study , 2012, Neurodegenerative Diseases.

[87]  J. Hardy,et al.  Widespread Lewy body and tau accumulation in childhood and adult onset dystonia-parkinsonism cases with PLA2G6 mutations , 2012, Neurobiology of Aging.

[88]  W. F. Abdo,et al.  CSF α-synuclein does not differentiate between parkinsonian disorders , 2012, Neurobiology of Aging.

[89]  P. Spano,et al.  Redistribution of DAT/α-Synuclein Complexes Visualized by “In Situ” Proximity Ligation Assay in Transgenic Mice Modelling Early Parkinson's Disease , 2011, PLoS ONE.

[90]  Janel O. Johnson,et al.  Clinical features, with video documentation, of the original familial lewy body parkinsonism caused by α‐synuclein triplication (Iowa kindred) , 2011, Movement disorders : official journal of the Movement Disorder Society.

[91]  Yu Wang,et al.  Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression , 2011, Annals of neurology.

[92]  B. Mollenhauer,et al.  Quantification of α-synuclein in cerebrospinal fluid as a biomarker candidate: review of the literature and considerations for future studies. , 2010, Biomarkers in medicine.

[93]  C. Sampaio,et al.  Worldwide frequency of G2019S LRRK2 mutation in Parkinson's disease: a systematic review. , 2010, Parkinsonism & related disorders.

[94]  P. Pástor,et al.  PINK1-linked parkinsonism is associated with Lewy body pathology. , 2010, Brain : a journal of neurology.

[95]  D. Dickson,et al.  Leucine-Rich Repeat Kinase 2 Gene-Associated Disease: Redefining Genotype-Phenotype Correlation , 2010, Neurodegenerative Diseases.

[96]  Z. Wszolek,et al.  Familial parkinsonism: study of original Sagamihara PARK8 (I2020T) kindred with variable clinicopathologic outcomes. , 2009, Parkinsonism & related disorders.

[97]  Angelo Antonini,et al.  Cost‐effectiveness of 123I‐FP‐CIT SPECT in the differential diagnosis of essential tremor and Parkinson's disease in Italy , 2008, Movement disorders : official journal of the Movement Disorder Society.

[98]  B. Oostra,et al.  The LRRK2 Arg1628Pro variant is a risk factor for Parkinson’s disease in the Chinese population , 2008, Neurogenetics.

[99]  Marguerite Wieler,et al.  Midbrain iron content in early Parkinson disease , 2008, Neurology.

[100]  N. Hattori,et al.  Neuropsychiatric and cognitive features in autosomal‐recessive early parkinsonism due to PINK1 mutations , 2007, Movement disorders : official journal of the Movement Disorder Society.

[101]  M. Farrer,et al.  Lrrk2 G2385R is an ancestral risk factor for Parkinson's disease in Asia. , 2007, Parkinsonism & related disorders.

[102]  D. Cordato,et al.  Dementia with Lewy bodies in an elderly Greek male due to α-synuclein gene mutation , 2006, Journal of Clinical Neuroscience.

[103]  A. Singleton,et al.  Parkinson's disease due to the R1441G mutation in Dardarin: A founder effect in the basques , 2006, Movement disorders : official journal of the Movement Disorder Society.

[104]  M. Farrer,et al.  Parkinsonism, Lrrk2 G2019S, and tau neuropathology , 2006, Neurology.

[105]  D. Allsop,et al.  Detection of oligomeric forms of α‐synuclein protein in human plasma as a potential biomarker for Parkinson's disease , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[106]  Thomas Meitinger,et al.  Mutations in LRRK2 Cause Autosomal-Dominant Parkinsonism with Pleomorphic Pathology , 2004, Neuron.

[107]  M. Cookson,et al.  α‐Synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[108]  Yoav Ben-Shlomo,et al.  The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. , 2002, Brain : a journal of neurology.

[109]  N. Quinn,et al.  Young‐onset Parkinson's disease revisited—clinical features, natural history, and mortality , 1998, Movement disorders : official journal of the Movement Disorder Society.

[110]  V. Dhawan,et al.  Differential diagnosis of parkinsonism with [18F]fluorodeoxyglucose and PET , 1998, Movement disorders : official journal of the Movement Disorder Society.

[111]  D. Eidelberg,et al.  [11C]Raclopride‐PET studies of the Huntington's disease rate of progression: Relevance of the trinucleotide repeat length , 1998, Annals of neurology.

[112]  Robert L. Nussbaum,et al.  Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease , 1997 .

[113]  J. Hughes,et al.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. , 1992, Journal of neurology, neurosurgery, and psychiatry.

[114]  J. Jankovic,et al.  Variable expression of Parkinson's disease , 1990, Neurology.

[115]  T. Joh,et al.  Neuropathology of immunohistochemically identified brainstem neurons in Parkinson's disease , 1990, Annals of neurology.

[116]  P. Yates,et al.  PATHOLOGICAL BASIS FOR NEUROTRANSMITTER CHANGES IN PARKINSON'S DISEASE , 1983, Neuropathology and applied neurobiology.

[117]  Dennis W Dickson,et al.  Neuropathology of Parkinson disease. , 2018, Parkinsonism & related disorders.

[118]  Young Eun Kim,et al.  Abstracts of the 21st International Congress of Parkinson's Disease and Movement Disorders. , 2017, Movement disorders : official journal of the Movement Disorder Society.

[119]  S. Gilman,et al.  Diagnostic criteria for Parkinson disease. , 1999, Archives of neurology.

[120]  Shobini L. Rao,et al.  Early onset Parkinson's disease: Are juvenile‐ and young‐onset different? , 1994, Movement disorders : official journal of the Movement Disorder Society.

[121]  N. Quinn,et al.  Young onset Parkinson's disease , 1987, Movement disorders : official journal of the Movement Disorder Society.

[122]  K. Jellinger,et al.  Overview of morphological changes in Parkinson's disease. , 1987, Advances in neurology.